BigNews.Biz - Jul 22,2012 - Mark M. Goodman, Professor of Radiology and Imaging Sciences, Psychiatry and Hematology and Oncology at Emory University will give a presentation on the “Development of Radiolabeled Monoamine Transporter Ligands to Study Neuropsychiatric Disorders” at the 2nd Neuropsychiatric Research and Development conference taking place on Sept 13-14, 2012 in San Francisco, CA.
Mark M. Goodman was named the inaugural Emory Professor in Imaging Science in 2007, awarded the Society of Nuclear Medicine 2010 Michael J. Welch Award for outstanding contributions to radiopharmaceutical sciences and the Society of Nuclear Medicine 2012 Paul C. Aebersold Award for outstanding achievement in basic nuclear medicine science. He has taken several monoamine transporter biomarkers from the bench to human trials such as dopamine transporter radioligands [123I]MMG-142/IPT and [18F]FECNT, serotonin transporter radioligands [11C]pZIENT, [11C]HOMADAM and [123I]mZIENT and the norepinephrine transporter radioligand [11C]MENET. He developed the first fluorine-18 labeled non natural amino acid to image intracranial tumors and prostate cancer and the non natural fatty acid [123I]BMIPP which has been commercially introduced in Japan as Cardiodine. His research is directed towards the development of new radiotracers for the study cocaine addiction, depression, anxiety, suicide, dementia and psychomotor disorders and the management of treatment of cancer and cardiovascular disorders.
GTC’s 2nd Neuropsychiatric Research and Development will discuss the latest breakthroughs, new drug targets, new models, neuroimaging, novel technologies and several other novel developments and therapeutics to combat neuropsychiatric disorders. The conference is also a part of the 2nd CNS Diseases World Summit. The Summit brings together the leading experts across the industry and academia to discuss the latest research and developments in the CNS field. The summit has four parallel tracks that focus on neurodegenerative conditions, neuropsychiatric disorders, pain research and therapeutics and CNS partnering and deal-making.
Join your colleagues at this exciting Neuropsychiatric conference and CNS summit, and hear from and meet with key representatives in the field including Charles B. Nemeroff at University of Miami, Stephen Brannan – VP at Takeda, Husseini Manji - Global Head of Neuroscience Therapeutic at Janssen, Barry Brand - Chief Executive Officer at CeNeRx, George Garibaldi - Global Head of CNS Clinical Development at F. Hoffmann-La Roche, Clinton D. Kilts at University of Arkansas, Phil Skolnick at NIDA NIH, and many more!